Drug Profile

Lamivudine/tenofovir disoproxil fumarate - Micro Labs

Alternative Names: HA620

Latest Information Update: 23 Feb 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Micro Labs
Class Antiretrovirals; Deoxyribonucleosides; Dideoxynucleosides; Phosphonic acids; Purines; Pyrimidine nucleosides; Small molecules
Mechanism of Action Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

23 Feb 2022 Lamivudine/tenofovir disoproxil fumarate is not yet available for HIV-1 infections in USA (PO)
06 Feb 2018 Chemical structure information added
25 Jan 2018 US FDA tentatively approves NDA for Lamivudine/tenofovir disoproxil fumarate in HIV-1 infections (Combination therapy with antiretrovirals)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com